COMMUNIQUÉS West-GlobeNewswire

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
09/05/2024
- FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension – BOSTON and ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Inhibikase [...]
Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
09/05/2024
Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will focus on increasing access to life [...]
Dental Influencers Alliance Attendees Praise Halo Dental Technologies’ Digital Mirror at Annual Get Together
09/05/2024
Waitlist for first-of-its-kind digital dental mirror announced, opening May 2024 for dentists and hygienists who want to be among the first to secure the Halo Digital Mirror. MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- [...]
Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
09/05/2024
SAN JOSE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]
Annexon Biosciences to Present at the Bank of America Health Care Conference
09/05/2024
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]
Stryker declares a $0.80 per share quarterly dividend
09/05/2024
Portage, Michigan, May 09, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.80 per share payable July 31, 2024 to shareholders of record at the [...]
Corbus Pharmaceuticals to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
09/05/2024
NORWOOD, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will [...]
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
09/05/2024
Over 17,500 total prescriptions for VOQUEZNA ® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full quarter of launch Cigna [...]
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
09/05/2024
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response (CR) Rate at Any Time in Bacillus Calmette Guerin (BCG)-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) First Patient Dosed in PIVOT- [...]
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
09/05/2024
Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024 On track to deliver additional analyses from BEACON and AURORA in Q2 2024 Plan [...]
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
09/05/2024
Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatment Topline 96-week data from ORIGIN 2 trial expected in [...]
Cerevance Presents at IAPRD XXIX World Congress on Parkinson’s Disease and Related Disorders
09/05/2024
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, will present an oral presentation at the upcoming International [...]
Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting
09/05/2024
CUPERTINO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Volta Medical Featured in Latest Consensus Statement from Leading International Cardiac Electrophysiology Societies on Atrial Fibrillation Ablation
09/05/2024
Published in the EP Europace Journal, the consensus statement highlights Volta’s AI Companion and the TAILORED-AF clinical trial. MARSEILLE, France, May 09, 2024 (GLOBE NEWSWIRE) -- Volta Medical, a pioneering health [...]
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update
09/05/2024
Design of Phase 2b trial for VYN201 in nonsegmental vitiligo finalized and on track to begin this quarter Phase 2b trial expected to enroll approximately 160 subjects with either active or stable nonsegmental vitiligo [...]
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research
09/05/2024
Shipment of MDMA active pharmaceutical ingredient (API) to Israel marks the Company’s first international export VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: [...]
Apnimed Announces Completion of Enrollment in Phase 3 LunAIRo Study of AD109, the Potential First Nighttime Oral Treatment for Obstructive Sleep Apnea
09/05/2024
- Apnimed to Present Rationale and Design of LunAIRo Phase 3 Study for AD109 at the ATS 2024 International Conference - Topline Phase 3 Data Expected in Mid-2025 CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- [...]
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights
09/05/2024
First patient dosed and continued enrollment in Phase 2 portion of the PYNNACLE trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Phase 1 data of rezatapopt [...]
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
09/05/2024
SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the [...]

Pages